肺動脈性肺高血圧症に対するフィンゴリモドの薬効評価

• Published in: 日本薬理学会年会要旨集 p. 1-LBS-18
• Main Authors: 藤原, 萌園, 山村, 彩, 鈴木, 良明, 山村, 寿男
• Format: Journal Article
• Language: Japanese
• Published: 公益社団法人 日本薬理学会 2020
• Subjects: smooth muscle
• ISSN: 2435-4953
• DOI: 10.1254/jpssuppl.93.0_1-LBS-18

Pulmonary arterial hypertension (PAH) is pathophysiologically characterized by vasoconstriction and vascular remodeling of the pulmonary artery. Pulmonary vascular remodeling is mainly mediated by the enhanced cell proliferation of pulmonary arterial smooth muscle cells (PASMCs). In this study, we examined the pharmacological effects of fingolimod on the development of PAH. The proliferation rate of PASMCs from idiopathic PAH (IPAH) patients was much higher than that of PASMCs from normal subjects. In normal-PASMCs, fingolimod at low concentrations did not affect the cell proliferation, whereas higher concentrations partly reduced the cell proliferation. On the other hand, the application of fingolimod clearly inhibited the proliferation of IPAH-PASMCs and the inhibitory effect was in a concentration-dependent manner. In monocrotaline-induced pulmonary hypertensive rats, intraperitoneal administration of fingolimod ameliorated both pulmonary vascular remodeling and right ventricular hypertrophy. In addition, fingolimod improved the mortality rate. Our results suggest that fingolimod blocks the development of PAH through inhibiting the excessive proliferation of PASMCs. Fingolimod may be a novel option for the treatment of PAH.